{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:27:36Z","timestamp":1786739256197,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>Cancer is a disease triggered by an uncontrolled proliferation of a cluster of cells, typically originating from a single cell. Sorafenib, a widely utilized pharmaceutical, has limitations in clinical use due to pharmacokinetic challenges and the development of resistance mechanisms. This investigation aimed to synthesize new sorafenib analogs and evaluated their activity against HepG2 cell lines, specifically targeting hepatocellular carcinoma (HCC). Seven sorafenib analogs were synthesized and identified by Fourier-transform infrared spectroscopy and 1H-NMR spectra. Cytotoxicity of the analogs was assessed on the human HepG2 cancer cell line by (3-(4, 5-dimethylthazolk-2-yl)-2, 5-diphenyl tetrazolium bromide) colorimetric assay. Results revealed that among the studied compounds, 4b exhibited the most pronounced cytotoxicity against cancer cells, surpassing even the efficacy of sorafenib. This suggested that small substitutions on the NH moiety play a crucial role in the activity against the human HepG2 liver cancer cell line. These findings provide valuable insights for the development of potential anticancer-targeting HCC.<\/jats:p>","DOI":"10.4103\/japtr.japtr_282_23","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T04:53:44Z","timestamp":1690952024000},"page":"274-279","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Synthesis, characterization, and antiproliferative evaluation of novel sorafenib analogs for the treatment of hepatocellular carcinoma"],"prefix":"10.4103","volume":"14","author":[{"given":"Marwan Imad","family":"Jihad","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mustansiriyah, Baghdad, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monther Faisal","family":"Mahdi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mustansiriyah, Baghdad, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"R1-20260204","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.bmcl.2009.04.014","article-title":"Design, synthesis and anticancer activities of hybrids of indole and barbituric acids \u2013Identification of highly promising leads","volume":"19","author":"Singh","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"R2-20260204","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/107327480301000207","article-title":"Overcoming multidrug resistance in cancer:An update on the clinical strategy of inhibiting P-glycoprotein","volume":"10","author":"Thomas","year":"2003","journal-title":"Cancer Control"},{"key":"R3-20260204","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1164\/rccm.202011-4063OC","article-title":"Air pollution, genetic factors, and the risk of lung cancer:A prospective study in the UK Biobank","volume":"204","author":"Huang","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R4-20260204","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/cas.14666","article-title":"New horizons of DNA adductome for exploring environmental causes of cancer","volume":"112","author":"Totsuka","year":"2021","journal-title":"Cancer Sci"},{"key":"R5-20260204","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3):Analysis of individual records for 37?513?025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"R6-20260204","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41419-021-03453-w","article-title":"Identification of a long non-coding RNA regulator of liver carcinoma cell survival","volume":"12","author":"Rybakova","year":"2021","journal-title":"Cell Death Dis"},{"key":"R7-20260204","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R8-20260204","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1590-8658(01)80062-1","article-title":"Hepatocellular carcinoma:Global epidemiology","volume":"33","author":"Tabor","year":"2001","journal-title":"Dig Liver Dis"},{"key":"R10-20260204","doi-asserted-by":"crossref","first-page":"104609","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors:A 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol Res"},{"key":"R12-20260204","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MCG.0000000000001375","article-title":"Association of gastric acid suppression and sorafenib efficacy in advanced hepatocellular carcinoma","volume":"55","author":"Razak","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"R13-20260204","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6602584","article-title":"Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on\/7 days off in patients with advanced, refractory solid tumours","volume":"92","author":"Awada","year":"2005","journal-title":"Br J Cancer"},{"key":"R14-20260204","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/annonc\/mdi310","article-title":"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on\/7 days off in patients with advanced, refractory solid tumors","volume":"16","author":"Moore","year":"2005","journal-title":"Ann Oncol"},{"key":"R15-20260204","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1111\/cts.13069","article-title":"Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma:A simulation study","volume":"14","author":"Panetta","year":"2021","journal-title":"Clin Transl Sci"},{"key":"R16-20260204","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bcpt.13525","article-title":"Methyl palmitate-A suitable adjuvant for Sorafenib therapy to reduce in vivo toxicity and to enhance anti-cancer effects on hepatocellular carcinoma cells","volume":"128","author":"Breeta","year":"2021","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R17-20260204","doi-asserted-by":"crossref","first-page":"116072","DOI":"10.1016\/j.taap.2022.116072","article-title":"Apigenin alleviates cancer drug sorafenib induced multiple toxic effects in Swiss albino mice via anti-oxidative stress","volume":"447","author":"Singh","year":"2022","journal-title":"Toxicol Appl Pharmacol"},{"key":"R18-20260204","doi-asserted-by":"crossref","first-page":"92","DOI":"10.36347\/sjmcr.2022.v10i02.010","article-title":"Inhabituel toxicity of sorafenib:Eryhema multiform:A new case report and review","volume":"2","author":"Aalaoui","year":"2022","journal-title":"Sch J Med Case Rep"},{"key":"R19-20260204","doi-asserted-by":"crossref","first-page":"e14351","DOI":"10.15252\/emmm.202114351","article-title":"YAP\/TAZ and ATF4 drive resistance to sorafenib in hepatocellular carcinoma by preventing ferroptosis","volume":"13","author":"Gao","year":"2021","journal-title":"EMBO Mol Med"},{"key":"R20-20260204","doi-asserted-by":"crossref","first-page":"951","DOI":"10.7150\/jca.52778","article-title":"Targeted inhibition of ACLY expression to reverse the resistance of sorafenib in hepatocellular carcinoma","volume":"13","author":"Sun","year":"2022","journal-title":"J Cancer"},{"key":"R21-20260204","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1248\/bpb.34.433","article-title":"Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib","volume":"34","author":"Shibayama","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"R22-20260204","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41388-020-01545-z","article-title":"Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma","volume":"40","author":"Yu","year":"2021","journal-title":"Oncogene"},{"key":"R23-20260204","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s00044-016-1667-y","article-title":"Design, synthesis, and cytostatic activity of novel pyrazine sorafenib analogs","volume":"25","author":"D\u017eoli\u0107","year":"2016","journal-title":"Med Chem Res"},{"key":"R24-20260204","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1055\/s-2006-942440","article-title":"Recent progress in Diaryl ether synthesis","volume":"2006","author":"Kikelj","year":"2006","journal-title":"Synthesis"},{"key":"R25-20260204","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.3390\/molecules23112853","article-title":"Pentafluorosulfanyl-containing triclocarban analogs with potent antimicrobial activity","volume":"23","author":"Pujol","year":"2018","journal-title":"Molecules"},{"key":"R26-20260204","doi-asserted-by":"crossref","first-page":"e51076","DOI":"10.1371\/journal.pone.0051076","article-title":"Autophagy protects against oxaliplatin-induced cell death via ER stress and ROS in Caco-2 cells","volume":"7","author":"Shi","year":"2012","journal-title":"PLoS One"},{"key":"R28-20260204","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1016\/j.bmc.2008.03.074","article-title":"Synthesis, cytostatic and anti-HIV evaluations of the new unsaturated acyclic C-5 pyrimidine nucleoside analogues","volume":"16","author":"Gazivoda","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"R29-20260204","doi-asserted-by":"crossref","first-page":"e0197044","DOI":"10.1371\/journal.pone.0197044","article-title":"Anticancer, antioxidant, and antibacterial activities of low molecular weight bioactive subfractions isolated from cultures of wood degrading fungus Cerrena unicolor","volume":"13","author":"Matuszewska","year":"2018","journal-title":"PLoS One"}],"container-title":["Journal of Advanced Pharmaceutical Technology &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/JAPTR.JAPTR_282_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:27:18Z","timestamp":1786735638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/JAPTR.JAPTR_282_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/japtr.japtr_282_23","relation":{},"ISSN":["2231-4040","0976-2094"],"issn-type":[{"value":"2231-4040","type":"print"},{"value":"0976-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2023-05-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}